Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 20/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288167 | 0.91 | GPR119 (0.70) | GPR119CYP2C9KCNH2 | |
| SCHEMBL757761 | 0.90 | GPR119 (0.69) | GPR119CYP2C9KCNH2 | |
| SCHEMBL3238901 | 0.89 | GPR119 (0.72) | GPR119CYP2C9 | |
| SCHEMBL1066161 | 0.86 | GPR119 (0.58) | GPR119CYP2C9 | |
| SCHEMBL761736 | 0.86 | GPR119 (0.58) | GPR119CYP2C9 | |
| SCHEMBL10170984 | 0.86 | GPR119 (0.56) | GPR119CYP2C9 | |
| SCHEMBL15991794 | 0.85 | GPR119 (1.00) | GPR119CYP2C9 | |
| SCHEMBL4491635 | 0.84 | GPR119 (1.00) | GPR119CYP2C9 | |
| SCHEMBL288614 | 0.84 | GPR119 (1.00) | GPR119CYP2C9 | |
| SCHEMBL1066545 | 0.82 | GPR119 (0.72) | GPR119CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2210886-B1 | PYRIMIDYL INDOLINE COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2015-09-23 | — | — | EP | disclosed |
| US-8232287-B2 | Pyrimidyl indoline compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-07-31 | — | — | US | disclosed |
| EP-2427450-A1 | GPR 119 MODULATORS | Pfizer Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2427448-A1 | Gpr 119 modulators | Pfizer Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20120052130-A1 | GPR 119 MODULATORS | PFIZER INC. | 2012-03-01 | — | — | US | disclosed |
| US-20120052130-A1 | GPR 119 MODULATORS | PFIZER INC. | 2012-03-01 | — | — | US | disclosed |
| US-20120052130-A1 | GPR 119 MODULATORS | PFIZER INC. | 2012-03-01 | — | — | US | disclosed |
| US-20100292259-A1 | PYRIMIDYL INDOLINE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-11-18 | — | — | US | disclosed |
| WO-2010128414-A1 | GPR 119 MODULATORS | PFIZER INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010128425-A1 | GPR 119 MODULATORS | PFIZER INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100285145-A1 | GPR 119 MODULATORS | PFIZER INC | 2010-11-11 | — | — | US | disclosed |
| US-20100285145-A1 | GPR 119 MODULATORS | PFIZER INC | 2010-11-11 | — | — | US | disclosed |
| US-20100285145-A1 | GPR 119 MODULATORS | PFIZER INC | 2010-11-11 | — | — | US | disclosed |
| EP-2210886-A1 | PYRIMIDYL INDOLINE COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2010-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120052130-A1 | GPR 119 MODULATORS | GPR119, GPR39, GPR65 | GPR119 1/4885CYP2C9 722/4885KCNH2 2403/4885 |
| US-20100285145-A1 | GPR 119 MODULATORS | GPR119, GPR65, GPR39 | GPR119 1/4885CYP2C9 1406/4885KCNH2 2347/4885 |
| US-20100292259-A1 | PYRIMIDYL INDOLINE COMPOUND | GPR119, SLC5A2, SLC5A1 | GPR119 1/4885CYP2C9 518/4885KCNH2 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.